nodes	percent_of_prediction	percent_of_DWPC	metapath
Fexofenadine—SLCO1A2—Prednisolone—multiple sclerosis	0.126	0.147	CbGbCtD
Fexofenadine—SLCO1A2—Prednisone—multiple sclerosis	0.119	0.139	CbGbCtD
Fexofenadine—SLCO1B3—Methotrexate—multiple sclerosis	0.0969	0.113	CbGbCtD
Fexofenadine—CYP2D6—Fingolimod—multiple sclerosis	0.0778	0.0905	CbGbCtD
Fexofenadine—SLCO1A2—Dexamethasone—multiple sclerosis	0.0744	0.0867	CbGbCtD
Fexofenadine—SLCO1A2—Methotrexate—multiple sclerosis	0.0598	0.0696	CbGbCtD
Fexofenadine—SLCO1B1—Methotrexate—multiple sclerosis	0.0564	0.0657	CbGbCtD
Fexofenadine—ABCB1—Methylprednisolone—multiple sclerosis	0.0532	0.0619	CbGbCtD
Fexofenadine—ABCB1—Mitoxantrone—multiple sclerosis	0.0388	0.0452	CbGbCtD
Fexofenadine—ABCB1—Betamethasone—multiple sclerosis	0.0346	0.0403	CbGbCtD
Fexofenadine—ABCB1—Prednisolone—multiple sclerosis	0.0341	0.0397	CbGbCtD
Fexofenadine—ABCB1—Prednisone—multiple sclerosis	0.0322	0.0375	CbGbCtD
Fexofenadine—ABCB1—Dexamethasone—multiple sclerosis	0.0201	0.0234	CbGbCtD
Fexofenadine—CYP2D6—Dexamethasone—multiple sclerosis	0.019	0.0221	CbGbCtD
Fexofenadine—ABCB1—Methotrexate—multiple sclerosis	0.0162	0.0188	CbGbCtD
Fexofenadine—Loperamide—POMC—multiple sclerosis	0.0015	1	CrCbGaD
Fexofenadine—Cardiac failure congestive—Methylprednisolone—multiple sclerosis	0.000778	0.00642	CcSEcCtD
Fexofenadine—Headache—Fingolimod—multiple sclerosis	0.000775	0.00639	CcSEcCtD
Fexofenadine—Injury—Triamcinolone—multiple sclerosis	0.00077	0.00635	CcSEcCtD
Fexofenadine—Injury—Methylprednisolone—multiple sclerosis	0.000768	0.00634	CcSEcCtD
Fexofenadine—Upper respiratory tract infection—Mitoxantrone—multiple sclerosis	0.000753	0.00622	CcSEcCtD
Fexofenadine—Increased appetite—Triamcinolone—multiple sclerosis	0.000753	0.00621	CcSEcCtD
Fexofenadine—Increased appetite—Methylprednisolone—multiple sclerosis	0.000751	0.0062	CcSEcCtD
Fexofenadine—Cough—Cladribine—multiple sclerosis	0.00075	0.00619	CcSEcCtD
Fexofenadine—Myalgia—Cladribine—multiple sclerosis	0.000731	0.00604	CcSEcCtD
Fexofenadine—Drowsiness—Mitoxantrone—multiple sclerosis	0.000723	0.00596	CcSEcCtD
Fexofenadine—Cardiac failure congestive—Betamethasone—multiple sclerosis	0.000708	0.00584	CcSEcCtD
Fexofenadine—Cardiac failure congestive—Dexamethasone—multiple sclerosis	0.000708	0.00584	CcSEcCtD
Fexofenadine—Injury—Betamethasone—multiple sclerosis	0.000698	0.00576	CcSEcCtD
Fexofenadine—Injury—Dexamethasone—multiple sclerosis	0.000698	0.00576	CcSEcCtD
Fexofenadine—Infection—Cladribine—multiple sclerosis	0.000697	0.00575	CcSEcCtD
Fexofenadine—Psychotic disorder—Methylprednisolone—multiple sclerosis	0.000689	0.00569	CcSEcCtD
Fexofenadine—Tachycardia—Cladribine—multiple sclerosis	0.000684	0.00565	CcSEcCtD
Fexofenadine—Increased appetite—Betamethasone—multiple sclerosis	0.000683	0.00564	CcSEcCtD
Fexofenadine—Increased appetite—Dexamethasone—multiple sclerosis	0.000683	0.00564	CcSEcCtD
Fexofenadine—Sinusitis—Mitoxantrone—multiple sclerosis	0.000678	0.00559	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Cladribine—multiple sclerosis	0.000639	0.00527	CcSEcCtD
Fexofenadine—Insomnia—Cladribine—multiple sclerosis	0.000634	0.00523	CcSEcCtD
Fexofenadine—Psychotic disorder—Betamethasone—multiple sclerosis	0.000627	0.00517	CcSEcCtD
Fexofenadine—Psychotic disorder—Dexamethasone—multiple sclerosis	0.000627	0.00517	CcSEcCtD
Fexofenadine—Dyspnoea—Cladribine—multiple sclerosis	0.000625	0.00516	CcSEcCtD
Fexofenadine—Somnolence—Cladribine—multiple sclerosis	0.000623	0.00514	CcSEcCtD
Fexofenadine—Cardiac failure congestive—Prednisone—multiple sclerosis	0.000616	0.00509	CcSEcCtD
Fexofenadine—Injury—Prednisone—multiple sclerosis	0.000608	0.00502	CcSEcCtD
Fexofenadine—Fatigue—Cladribine—multiple sclerosis	0.000604	0.00499	CcSEcCtD
Fexofenadine—Pain—Cladribine—multiple sclerosis	0.0006	0.00495	CcSEcCtD
Fexofenadine—Increased appetite—Prednisone—multiple sclerosis	0.000595	0.00491	CcSEcCtD
Fexofenadine—Myalgia—Azathioprine—multiple sclerosis	0.000595	0.00491	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Cladribine—multiple sclerosis	0.000573	0.00473	CcSEcCtD
Fexofenadine—Upper respiratory tract infection—Triamcinolone—multiple sclerosis	0.000568	0.00469	CcSEcCtD
Fexofenadine—Infection—Azathioprine—multiple sclerosis	0.000566	0.00467	CcSEcCtD
Fexofenadine—Urticaria—Cladribine—multiple sclerosis	0.000557	0.0046	CcSEcCtD
Fexofenadine—Abdominal pain—Cladribine—multiple sclerosis	0.000554	0.00457	CcSEcCtD
Fexofenadine—Body temperature increased—Cladribine—multiple sclerosis	0.000554	0.00457	CcSEcCtD
Fexofenadine—Back pain—Mitoxantrone—multiple sclerosis	0.000546	0.00451	CcSEcCtD
Fexofenadine—Psychotic disorder—Prednisone—multiple sclerosis	0.000546	0.00451	CcSEcCtD
Fexofenadine—Vision blurred—Mitoxantrone—multiple sclerosis	0.000532	0.00439	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.000519	0.00429	CcSEcCtD
Fexofenadine—Hypersensitivity—Cladribine—multiple sclerosis	0.000517	0.00426	CcSEcCtD
Fexofenadine—Epistaxis—Triamcinolone—multiple sclerosis	0.000514	0.00424	CcSEcCtD
Fexofenadine—Asthenia—Cladribine—multiple sclerosis	0.000503	0.00415	CcSEcCtD
Fexofenadine—Pruritus—Cladribine—multiple sclerosis	0.000496	0.00409	CcSEcCtD
Fexofenadine—Cough—Mitoxantrone—multiple sclerosis	0.000493	0.00407	CcSEcCtD
Fexofenadine—Myalgia—Mitoxantrone—multiple sclerosis	0.000481	0.00397	CcSEcCtD
Fexofenadine—Diarrhoea—Cladribine—multiple sclerosis	0.00048	0.00396	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Azathioprine—multiple sclerosis	0.000466	0.00385	CcSEcCtD
Fexofenadine—Dizziness—Cladribine—multiple sclerosis	0.000464	0.00383	CcSEcCtD
Fexofenadine—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000461	0.0038	CcSEcCtD
Fexofenadine—Infection—Mitoxantrone—multiple sclerosis	0.000458	0.00378	CcSEcCtD
Fexofenadine—Body temperature increased—Azathioprine—multiple sclerosis	0.000451	0.00372	CcSEcCtD
Fexofenadine—Abdominal pain—Azathioprine—multiple sclerosis	0.000451	0.00372	CcSEcCtD
Fexofenadine—Tachycardia—Mitoxantrone—multiple sclerosis	0.00045	0.00371	CcSEcCtD
Fexofenadine—Vomiting—Cladribine—multiple sclerosis	0.000446	0.00368	CcSEcCtD
Fexofenadine—Rash—Cladribine—multiple sclerosis	0.000442	0.00365	CcSEcCtD
Fexofenadine—Dermatitis—Cladribine—multiple sclerosis	0.000442	0.00364	CcSEcCtD
Fexofenadine—Headache—Cladribine—multiple sclerosis	0.000439	0.00362	CcSEcCtD
Fexofenadine—Vision blurred—Prednisolone—multiple sclerosis	0.000437	0.0036	CcSEcCtD
Fexofenadine—Angioedema—Prednisolone—multiple sclerosis	0.000423	0.00349	CcSEcCtD
Fexofenadine—Hypersensitivity—Azathioprine—multiple sclerosis	0.00042	0.00347	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.00042	0.00347	CcSEcCtD
Fexofenadine—Nausea—Cladribine—multiple sclerosis	0.000416	0.00344	CcSEcCtD
Fexofenadine—Back pain—Triamcinolone—multiple sclerosis	0.000412	0.0034	CcSEcCtD
Fexofenadine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000411	0.00339	CcSEcCtD
Fexofenadine—Somnolence—Mitoxantrone—multiple sclerosis	0.00041	0.00338	CcSEcCtD
Fexofenadine—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000406	0.00335	CcSEcCtD
Fexofenadine—Fatigue—Mitoxantrone—multiple sclerosis	0.000397	0.00328	CcSEcCtD
Fexofenadine—Pain—Mitoxantrone—multiple sclerosis	0.000394	0.00325	CcSEcCtD
Fexofenadine—Diarrhoea—Azathioprine—multiple sclerosis	0.00039	0.00322	CcSEcCtD
Fexofenadine—Angioedema—Triamcinolone—multiple sclerosis	0.000389	0.00321	CcSEcCtD
Fexofenadine—Angioedema—Methylprednisolone—multiple sclerosis	0.000388	0.00321	CcSEcCtD
Fexofenadine—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000387	0.00319	CcSEcCtD
Fexofenadine—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000378	0.00312	CcSEcCtD
Fexofenadine—Dizziness—Azathioprine—multiple sclerosis	0.000377	0.00311	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000377	0.00311	CcSEcCtD
Fexofenadine—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000375	0.0031	CcSEcCtD
Fexofenadine—Cough—Triamcinolone—multiple sclerosis	0.000372	0.00307	CcSEcCtD
Fexofenadine—Tachycardia—Prednisolone—multiple sclerosis	0.000369	0.00305	CcSEcCtD
Fexofenadine—Urticaria—Mitoxantrone—multiple sclerosis	0.000366	0.00302	CcSEcCtD
Fexofenadine—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000364	0.00301	CcSEcCtD
Fexofenadine—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000364	0.00301	CcSEcCtD
Fexofenadine—Myalgia—Triamcinolone—multiple sclerosis	0.000363	0.00299	CcSEcCtD
Fexofenadine—Vomiting—Azathioprine—multiple sclerosis	0.000362	0.00299	CcSEcCtD
Fexofenadine—Myalgia—Methylprednisolone—multiple sclerosis	0.000362	0.00299	CcSEcCtD
Fexofenadine—Drowsiness—Methotrexate—multiple sclerosis	0.00036	0.00297	CcSEcCtD
Fexofenadine—Rash—Azathioprine—multiple sclerosis	0.000359	0.00297	CcSEcCtD
Fexofenadine—Dermatitis—Azathioprine—multiple sclerosis	0.000359	0.00296	CcSEcCtD
Fexofenadine—Flushing—Prednisone—multiple sclerosis	0.000359	0.00296	CcSEcCtD
Fexofenadine—Headache—Azathioprine—multiple sclerosis	0.000357	0.00295	CcSEcCtD
Fexofenadine—Dry mouth—Triamcinolone—multiple sclerosis	0.000355	0.00293	CcSEcCtD
Fexofenadine—Angioedema—Dexamethasone—multiple sclerosis	0.000353	0.00291	CcSEcCtD
Fexofenadine—Angioedema—Betamethasone—multiple sclerosis	0.000353	0.00291	CcSEcCtD
Fexofenadine—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000348	0.00287	CcSEcCtD
Fexofenadine—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000347	0.00286	CcSEcCtD
Fexofenadine—Infection—Triamcinolone—multiple sclerosis	0.000345	0.00285	CcSEcCtD
Fexofenadine—Infection—Methylprednisolone—multiple sclerosis	0.000345	0.00284	CcSEcCtD
Fexofenadine—Insomnia—Prednisolone—multiple sclerosis	0.000342	0.00282	CcSEcCtD
Fexofenadine—Epistaxis—Methotrexate—multiple sclerosis	0.00034	0.0028	CcSEcCtD
Fexofenadine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.00034	0.0028	CcSEcCtD
Fexofenadine—Tachycardia—Triamcinolone—multiple sclerosis	0.000339	0.0028	CcSEcCtD
Fexofenadine—Nausea—Azathioprine—multiple sclerosis	0.000339	0.00279	CcSEcCtD
Fexofenadine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000339	0.00279	CcSEcCtD
Fexofenadine—Asthenia—Mitoxantrone—multiple sclerosis	0.000331	0.00273	CcSEcCtD
Fexofenadine—Myalgia—Betamethasone—multiple sclerosis	0.000329	0.00272	CcSEcCtD
Fexofenadine—Myalgia—Dexamethasone—multiple sclerosis	0.000329	0.00272	CcSEcCtD
Fexofenadine—Pain—Prednisolone—multiple sclerosis	0.000323	0.00267	CcSEcCtD
Fexofenadine—Vision blurred—Prednisone—multiple sclerosis	0.000317	0.00262	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000317	0.00261	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000316	0.00261	CcSEcCtD
Fexofenadine—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000315	0.0026	CcSEcCtD
Fexofenadine—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000315	0.0026	CcSEcCtD
Fexofenadine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000315	0.0026	CcSEcCtD
Fexofenadine—Insomnia—Triamcinolone—multiple sclerosis	0.000314	0.0026	CcSEcCtD
Fexofenadine—Insomnia—Methylprednisolone—multiple sclerosis	0.000314	0.00259	CcSEcCtD
Fexofenadine—Infection—Betamethasone—multiple sclerosis	0.000313	0.00259	CcSEcCtD
Fexofenadine—Infection—Dexamethasone—multiple sclerosis	0.000313	0.00259	CcSEcCtD
Fexofenadine—Dyspnoea—Triamcinolone—multiple sclerosis	0.00031	0.00256	CcSEcCtD
Fexofenadine—Agitation—Prednisone—multiple sclerosis	0.000309	0.00255	CcSEcCtD
Fexofenadine—Tachycardia—Betamethasone—multiple sclerosis	0.000308	0.00254	CcSEcCtD
Fexofenadine—Tachycardia—Dexamethasone—multiple sclerosis	0.000308	0.00254	CcSEcCtD
Fexofenadine—Angioedema—Prednisone—multiple sclerosis	0.000308	0.00254	CcSEcCtD
Fexofenadine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000306	0.00253	CcSEcCtD
Fexofenadine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000305	0.00252	CcSEcCtD
Fexofenadine—Urticaria—Prednisolone—multiple sclerosis	0.0003	0.00248	CcSEcCtD
Fexofenadine—Fatigue—Triamcinolone—multiple sclerosis	0.0003	0.00247	CcSEcCtD
Fexofenadine—Fatigue—Methylprednisolone—multiple sclerosis	0.000299	0.00247	CcSEcCtD
Fexofenadine—Pain—Triamcinolone—multiple sclerosis	0.000297	0.00245	CcSEcCtD
Fexofenadine—Vomiting—Mitoxantrone—multiple sclerosis	0.000293	0.00242	CcSEcCtD
Fexofenadine—Rash—Mitoxantrone—multiple sclerosis	0.000291	0.0024	CcSEcCtD
Fexofenadine—Dermatitis—Mitoxantrone—multiple sclerosis	0.00029	0.0024	CcSEcCtD
Fexofenadine—Headache—Mitoxantrone—multiple sclerosis	0.000289	0.00238	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000287	0.00237	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000287	0.00237	CcSEcCtD
Fexofenadine—Myalgia—Prednisone—multiple sclerosis	0.000287	0.00237	CcSEcCtD
Fexofenadine—Insomnia—Betamethasone—multiple sclerosis	0.000285	0.00235	CcSEcCtD
Fexofenadine—Insomnia—Dexamethasone—multiple sclerosis	0.000285	0.00235	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000284	0.00234	CcSEcCtD
Fexofenadine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000279	0.0023	CcSEcCtD
Fexofenadine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000278	0.00229	CcSEcCtD
Fexofenadine—Dyspepsia—Betamethasone—multiple sclerosis	0.000278	0.00229	CcSEcCtD
Fexofenadine—Urticaria—Triamcinolone—multiple sclerosis	0.000276	0.00228	CcSEcCtD
Fexofenadine—Urticaria—Methylprednisolone—multiple sclerosis	0.000276	0.00227	CcSEcCtD
Fexofenadine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000275	0.00227	CcSEcCtD
Fexofenadine—Anaphylactic shock—Prednisone—multiple sclerosis	0.000275	0.00227	CcSEcCtD
Fexofenadine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000274	0.00226	CcSEcCtD
Fexofenadine—Nausea—Mitoxantrone—multiple sclerosis	0.000274	0.00226	CcSEcCtD
Fexofenadine—Infection—Prednisone—multiple sclerosis	0.000273	0.00225	CcSEcCtD
Fexofenadine—Back pain—Methotrexate—multiple sclerosis	0.000272	0.00225	CcSEcCtD
Fexofenadine—Fatigue—Betamethasone—multiple sclerosis	0.000272	0.00224	CcSEcCtD
Fexofenadine—Fatigue—Dexamethasone—multiple sclerosis	0.000272	0.00224	CcSEcCtD
Fexofenadine—Pain—Dexamethasone—multiple sclerosis	0.00027	0.00223	CcSEcCtD
Fexofenadine—Pain—Betamethasone—multiple sclerosis	0.00027	0.00223	CcSEcCtD
Fexofenadine—Tachycardia—Prednisone—multiple sclerosis	0.000268	0.00221	CcSEcCtD
Fexofenadine—Vision blurred—Methotrexate—multiple sclerosis	0.000265	0.00219	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000258	0.00213	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000258	0.00213	CcSEcCtD
Fexofenadine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000256	0.00211	CcSEcCtD
Fexofenadine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000256	0.00211	CcSEcCtD
Fexofenadine—Urticaria—Dexamethasone—multiple sclerosis	0.000251	0.00207	CcSEcCtD
Fexofenadine—Urticaria—Betamethasone—multiple sclerosis	0.000251	0.00207	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.00025	0.00207	CcSEcCtD
Fexofenadine—Dizziness—Prednisolone—multiple sclerosis	0.00025	0.00206	CcSEcCtD
Fexofenadine—Asthenia—Triamcinolone—multiple sclerosis	0.000249	0.00206	CcSEcCtD
Fexofenadine—Abdominal pain—Dexamethasone—multiple sclerosis	0.000249	0.00206	CcSEcCtD
Fexofenadine—Body temperature increased—Dexamethasone—multiple sclerosis	0.000249	0.00206	CcSEcCtD
Fexofenadine—Abdominal pain—Betamethasone—multiple sclerosis	0.000249	0.00206	CcSEcCtD
Fexofenadine—Body temperature increased—Betamethasone—multiple sclerosis	0.000249	0.00206	CcSEcCtD
Fexofenadine—Asthenia—Methylprednisolone—multiple sclerosis	0.000249	0.00205	CcSEcCtD
Fexofenadine—Insomnia—Prednisone—multiple sclerosis	0.000248	0.00205	CcSEcCtD
Fexofenadine—Pruritus—Triamcinolone—multiple sclerosis	0.000246	0.00203	CcSEcCtD
Fexofenadine—Cough—Methotrexate—multiple sclerosis	0.000245	0.00203	CcSEcCtD
Fexofenadine—Pruritus—Methylprednisolone—multiple sclerosis	0.000245	0.00203	CcSEcCtD
Fexofenadine—Dyspepsia—Prednisone—multiple sclerosis	0.000242	0.002	CcSEcCtD
Fexofenadine—Myalgia—Methotrexate—multiple sclerosis	0.00024	0.00198	CcSEcCtD
Fexofenadine—Rash—Prednisolone—multiple sclerosis	0.000238	0.00197	CcSEcCtD
Fexofenadine—Dermatitis—Prednisolone—multiple sclerosis	0.000238	0.00197	CcSEcCtD
Fexofenadine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000237	0.00196	CcSEcCtD
Fexofenadine—Fatigue—Prednisone—multiple sclerosis	0.000237	0.00195	CcSEcCtD
Fexofenadine—Headache—Prednisolone—multiple sclerosis	0.000237	0.00195	CcSEcCtD
Fexofenadine—Dizziness—Triamcinolone—multiple sclerosis	0.00023	0.0019	CcSEcCtD
Fexofenadine—Anaphylactic shock—Methotrexate—multiple sclerosis	0.00023	0.00189	CcSEcCtD
Fexofenadine—Dizziness—Methylprednisolone—multiple sclerosis	0.000229	0.00189	CcSEcCtD
Fexofenadine—Infection—Methotrexate—multiple sclerosis	0.000228	0.00188	CcSEcCtD
Fexofenadine—Asthenia—Betamethasone—multiple sclerosis	0.000226	0.00187	CcSEcCtD
Fexofenadine—Asthenia—Dexamethasone—multiple sclerosis	0.000226	0.00187	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000225	0.00185	CcSEcCtD
Fexofenadine—Nausea—Prednisolone—multiple sclerosis	0.000225	0.00185	CcSEcCtD
Fexofenadine—Pruritus—Dexamethasone—multiple sclerosis	0.000223	0.00184	CcSEcCtD
Fexofenadine—Pruritus—Betamethasone—multiple sclerosis	0.000223	0.00184	CcSEcCtD
Fexofenadine—Vomiting—Triamcinolone—multiple sclerosis	0.000221	0.00182	CcSEcCtD
Fexofenadine—Vomiting—Methylprednisolone—multiple sclerosis	0.000221	0.00182	CcSEcCtD
Fexofenadine—Rash—Triamcinolone—multiple sclerosis	0.000219	0.00181	CcSEcCtD
Fexofenadine—Dermatitis—Triamcinolone—multiple sclerosis	0.000219	0.00181	CcSEcCtD
Fexofenadine—Rash—Methylprednisolone—multiple sclerosis	0.000219	0.00181	CcSEcCtD
Fexofenadine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000219	0.0018	CcSEcCtD
Fexofenadine—Urticaria—Prednisone—multiple sclerosis	0.000218	0.0018	CcSEcCtD
Fexofenadine—Headache—Triamcinolone—multiple sclerosis	0.000218	0.0018	CcSEcCtD
Fexofenadine—Headache—Methylprednisolone—multiple sclerosis	0.000217	0.00179	CcSEcCtD
Fexofenadine—Body temperature increased—Prednisone—multiple sclerosis	0.000217	0.00179	CcSEcCtD
Fexofenadine—Abdominal pain—Prednisone—multiple sclerosis	0.000217	0.00179	CcSEcCtD
Fexofenadine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000216	0.00178	CcSEcCtD
Fexofenadine—Diarrhoea—Betamethasone—multiple sclerosis	0.000216	0.00178	CcSEcCtD
Fexofenadine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000209	0.00173	CcSEcCtD
Fexofenadine—Dizziness—Betamethasone—multiple sclerosis	0.000209	0.00172	CcSEcCtD
Fexofenadine—Dizziness—Dexamethasone—multiple sclerosis	0.000209	0.00172	CcSEcCtD
Fexofenadine—Insomnia—Methotrexate—multiple sclerosis	0.000208	0.00171	CcSEcCtD
Fexofenadine—Nausea—Triamcinolone—multiple sclerosis	0.000207	0.0017	CcSEcCtD
Fexofenadine—Nausea—Methylprednisolone—multiple sclerosis	0.000206	0.0017	CcSEcCtD
Fexofenadine—Dyspnoea—Methotrexate—multiple sclerosis	0.000205	0.00169	CcSEcCtD
Fexofenadine—Somnolence—Methotrexate—multiple sclerosis	0.000204	0.00168	CcSEcCtD
Fexofenadine—Hypersensitivity—Prednisone—multiple sclerosis	0.000202	0.00167	CcSEcCtD
Fexofenadine—Dyspepsia—Methotrexate—multiple sclerosis	0.000202	0.00167	CcSEcCtD
Fexofenadine—Vomiting—Dexamethasone—multiple sclerosis	0.000201	0.00166	CcSEcCtD
Fexofenadine—Vomiting—Betamethasone—multiple sclerosis	0.000201	0.00166	CcSEcCtD
Fexofenadine—Rash—Betamethasone—multiple sclerosis	0.000199	0.00164	CcSEcCtD
Fexofenadine—Rash—Dexamethasone—multiple sclerosis	0.000199	0.00164	CcSEcCtD
Fexofenadine—Dermatitis—Dexamethasone—multiple sclerosis	0.000199	0.00164	CcSEcCtD
Fexofenadine—Dermatitis—Betamethasone—multiple sclerosis	0.000199	0.00164	CcSEcCtD
Fexofenadine—Fatigue—Methotrexate—multiple sclerosis	0.000198	0.00163	CcSEcCtD
Fexofenadine—Headache—Betamethasone—multiple sclerosis	0.000198	0.00163	CcSEcCtD
Fexofenadine—Headache—Dexamethasone—multiple sclerosis	0.000198	0.00163	CcSEcCtD
Fexofenadine—Asthenia—Prednisone—multiple sclerosis	0.000197	0.00163	CcSEcCtD
Fexofenadine—Pain—Methotrexate—multiple sclerosis	0.000196	0.00162	CcSEcCtD
Fexofenadine—Pruritus—Prednisone—multiple sclerosis	0.000194	0.0016	CcSEcCtD
Fexofenadine—Diarrhoea—Prednisone—multiple sclerosis	0.000188	0.00155	CcSEcCtD
Fexofenadine—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000188	0.00155	CcSEcCtD
Fexofenadine—Nausea—Betamethasone—multiple sclerosis	0.000187	0.00155	CcSEcCtD
Fexofenadine—Nausea—Dexamethasone—multiple sclerosis	0.000187	0.00155	CcSEcCtD
Fexofenadine—Urticaria—Methotrexate—multiple sclerosis	0.000182	0.00151	CcSEcCtD
Fexofenadine—Dizziness—Prednisone—multiple sclerosis	0.000182	0.0015	CcSEcCtD
Fexofenadine—Abdominal pain—Methotrexate—multiple sclerosis	0.000182	0.0015	CcSEcCtD
Fexofenadine—Body temperature increased—Methotrexate—multiple sclerosis	0.000182	0.0015	CcSEcCtD
Fexofenadine—Vomiting—Prednisone—multiple sclerosis	0.000175	0.00144	CcSEcCtD
Fexofenadine—Rash—Prednisone—multiple sclerosis	0.000173	0.00143	CcSEcCtD
Fexofenadine—Dermatitis—Prednisone—multiple sclerosis	0.000173	0.00143	CcSEcCtD
Fexofenadine—Headache—Prednisone—multiple sclerosis	0.000172	0.00142	CcSEcCtD
Fexofenadine—Hypersensitivity—Methotrexate—multiple sclerosis	0.000169	0.0014	CcSEcCtD
Fexofenadine—Asthenia—Methotrexate—multiple sclerosis	0.000165	0.00136	CcSEcCtD
Fexofenadine—Nausea—Prednisone—multiple sclerosis	0.000163	0.00135	CcSEcCtD
Fexofenadine—Pruritus—Methotrexate—multiple sclerosis	0.000162	0.00134	CcSEcCtD
Fexofenadine—Diarrhoea—Methotrexate—multiple sclerosis	0.000157	0.0013	CcSEcCtD
Fexofenadine—Dizziness—Methotrexate—multiple sclerosis	0.000152	0.00125	CcSEcCtD
Fexofenadine—Vomiting—Methotrexate—multiple sclerosis	0.000146	0.0012	CcSEcCtD
Fexofenadine—Rash—Methotrexate—multiple sclerosis	0.000145	0.00119	CcSEcCtD
Fexofenadine—Dermatitis—Methotrexate—multiple sclerosis	0.000145	0.00119	CcSEcCtD
Fexofenadine—Headache—Methotrexate—multiple sclerosis	0.000144	0.00119	CcSEcCtD
Fexofenadine—Nausea—Methotrexate—multiple sclerosis	0.000136	0.00113	CcSEcCtD
Fexofenadine—SLCO1B3—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000114	0.00625	CbGpPWpGaD
Fexofenadine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000112	0.00614	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—HLA-DRA—multiple sclerosis	0.00011	0.00603	CbGpPWpGaD
Fexofenadine—SLCO1B1—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000109	0.00601	CbGpPWpGaD
Fexofenadine—SLCO1B3—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000109	0.006	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000107	0.00586	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000107	0.00586	CbGpPWpGaD
Fexofenadine—SLCO2B1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000106	0.00582	CbGpPWpGaD
Fexofenadine—HRH1—G alpha (q) signalling events—GPR65—multiple sclerosis	0.000105	0.00577	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—FOXP3—multiple sclerosis	0.000104	0.00569	CbGpPWpGaD
Fexofenadine—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	9.58e-05	0.00526	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—HLA-G—multiple sclerosis	9.41e-05	0.00517	CbGpPWpGaD
Fexofenadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—multiple sclerosis	9.4e-05	0.00516	CbGpPWpGaD
Fexofenadine—SLCO1A2—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	8.94e-05	0.00491	CbGpPWpGaD
Fexofenadine—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	8.81e-05	0.00484	CbGpPWpGaD
Fexofenadine—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	8.81e-05	0.00484	CbGpPWpGaD
Fexofenadine—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	8.69e-05	0.00477	CbGpPWpGaD
Fexofenadine—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	8.69e-05	0.00477	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	8.64e-05	0.00474	CbGpPWpGaD
Fexofenadine—SLCO1A2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	8.58e-05	0.00471	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	8.39e-05	0.00461	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	8.39e-05	0.00461	CbGpPWpGaD
Fexofenadine—SLCO2B1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	8.38e-05	0.0046	CbGpPWpGaD
Fexofenadine—SLCO1B3—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	8.27e-05	0.00454	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	8.16e-05	0.00448	CbGpPWpGaD
Fexofenadine—HRH1—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	8.12e-05	0.00446	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—CD28—multiple sclerosis	7.92e-05	0.00435	CbGpPWpGaD
Fexofenadine—SLCO1B1—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	7.64e-05	0.0042	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	7.58e-05	0.00416	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	7.52e-05	0.00413	CbGpPWpGaD
Fexofenadine—HRH1—IL-4 Signaling Pathway—TYK2—multiple sclerosis	7.49e-05	0.00411	CbGpPWpGaD
Fexofenadine—HRH1—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	7.43e-05	0.00408	CbGpPWpGaD
Fexofenadine—SLCO2B1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	7.4e-05	0.00407	CbGpPWpGaD
Fexofenadine—SLCO1B1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	7.33e-05	0.00403	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—CD40—multiple sclerosis	7.23e-05	0.00397	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	7.17e-05	0.00394	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	7.17e-05	0.00394	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	7.13e-05	0.00392	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	6.96e-05	0.00382	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—SRM—multiple sclerosis	6.75e-05	0.00371	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—S1PR1—multiple sclerosis	6.58e-05	0.00361	CbGpPWpGaD
Fexofenadine—SLCO1B3—Transmembrane transport of small molecules—AQP4—multiple sclerosis	6.54e-05	0.00359	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	6.52e-05	0.00358	CbGpPWpGaD
Fexofenadine—SLCO1A2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	6.5e-05	0.00357	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	6.37e-05	0.0035	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	6.37e-05	0.0035	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	6.28e-05	0.00345	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	5.87e-05	0.00322	CbGpPWpGaD
Fexofenadine—SLCO1B3—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	5.78e-05	0.00317	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—CD86—multiple sclerosis	5.65e-05	0.00311	CbGpPWpGaD
Fexofenadine—SLCO1B1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	5.56e-05	0.00305	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	5.54e-05	0.00305	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—IL10—multiple sclerosis	5.54e-05	0.00305	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—IL4—multiple sclerosis	5.39e-05	0.00296	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—GPR65—multiple sclerosis	5.3e-05	0.00291	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—SRM—multiple sclerosis	5.3e-05	0.00291	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	5.27e-05	0.0029	CbGpPWpGaD
Fexofenadine—SLCO2B1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	5.25e-05	0.00288	CbGpPWpGaD
Fexofenadine—HRH1—IL-4 Signaling Pathway—STAT3—multiple sclerosis	5.24e-05	0.00288	CbGpPWpGaD
Fexofenadine—SLCO1A2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	5.14e-05	0.00282	CbGpPWpGaD
Fexofenadine—HRH1—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	5.1e-05	0.0028	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—FAS—multiple sclerosis	4.97e-05	0.00273	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	4.94e-05	0.00271	CbGpPWpGaD
Fexofenadine—HRH1—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	4.92e-05	0.0027	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	4.89e-05	0.00268	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—CCR1—multiple sclerosis	4.85e-05	0.00266	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—CXCL13—multiple sclerosis	4.85e-05	0.00266	CbGpPWpGaD
Fexofenadine—HRH1—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	4.79e-05	0.00263	CbGpPWpGaD
Fexofenadine—HRH1—IL-4 Signaling Pathway—MAPK1—multiple sclerosis	4.77e-05	0.00262	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—CYP24A1—multiple sclerosis	4.75e-05	0.00261	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—CYP27B1—multiple sclerosis	4.75e-05	0.00261	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.65e-05	0.00255	CbGpPWpGaD
Fexofenadine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.6e-05	0.00253	CbGpPWpGaD
Fexofenadine—SLCO1A2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	4.54e-05	0.00249	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	4.54e-05	0.00249	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—SRM—multiple sclerosis	4.53e-05	0.00249	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	4.46e-05	0.00245	CbGpPWpGaD
Fexofenadine—HRH1—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	4.42e-05	0.00243	CbGpPWpGaD
Fexofenadine—SLCO1B1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	4.39e-05	0.00241	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	4.37e-05	0.0024	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—GPC5—multiple sclerosis	4.35e-05	0.00239	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	4.22e-05	0.00232	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—CD80—multiple sclerosis	4.12e-05	0.00227	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	4.1e-05	0.00225	CbGpPWpGaD
Fexofenadine—SLCO1B3—SLC-mediated transmembrane transport—ALB—multiple sclerosis	4.1e-05	0.00225	CbGpPWpGaD
Fexofenadine—SLCO1B1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.88e-05	0.00213	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	3.79e-05	0.00208	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—CYP27B1—multiple sclerosis	3.73e-05	0.00205	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—CYP24A1—multiple sclerosis	3.73e-05	0.00205	CbGpPWpGaD
Fexofenadine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.73e-05	0.00205	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—S1PR1—multiple sclerosis	3.72e-05	0.00204	CbGpPWpGaD
Fexofenadine—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	3.67e-05	0.00202	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.65e-05	0.002	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—RRM1—multiple sclerosis	3.6e-05	0.00198	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	3.57e-05	0.00196	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—CCL3—multiple sclerosis	3.45e-05	0.0019	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—GPC5—multiple sclerosis	3.42e-05	0.00188	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	3.41e-05	0.00187	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—S1PR1—multiple sclerosis	3.37e-05	0.00185	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—PTGER4—multiple sclerosis	3.33e-05	0.00183	CbGpPWpGaD
Fexofenadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	3.32e-05	0.00182	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	3.26e-05	0.00179	CbGpPWpGaD
Fexofenadine—SLCO1A2—SLC-mediated transmembrane transport—ALB—multiple sclerosis	3.22e-05	0.00177	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—CXCR3—multiple sclerosis	3.21e-05	0.00176	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—CYP27B1—multiple sclerosis	3.19e-05	0.00175	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—CYP24A1—multiple sclerosis	3.19e-05	0.00175	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—RGS1—multiple sclerosis	3.16e-05	0.00174	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—CCR2—multiple sclerosis	3.12e-05	0.00172	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.12e-05	0.00171	CbGpPWpGaD
Fexofenadine—HRH1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	3.09e-05	0.00169	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—GPR65—multiple sclerosis	3e-05	0.00165	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	2.93e-05	0.00161	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—GPC5—multiple sclerosis	2.92e-05	0.0016	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	2.91e-05	0.0016	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—IL2—multiple sclerosis	2.9e-05	0.00159	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—CNR1—multiple sclerosis	2.88e-05	0.00158	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—RGS1—multiple sclerosis	2.87e-05	0.00158	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	2.87e-05	0.00157	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—RRM1—multiple sclerosis	2.83e-05	0.00155	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.79e-05	0.00153	CbGpPWpGaD
Fexofenadine—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	2.78e-05	0.00153	CbGpPWpGaD
Fexofenadine—SLCO1B1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	2.75e-05	0.00151	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—CCR1—multiple sclerosis	2.74e-05	0.0015	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—CXCL13—multiple sclerosis	2.74e-05	0.0015	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—GPR65—multiple sclerosis	2.72e-05	0.00149	CbGpPWpGaD
Fexofenadine—SLCO2B1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.67e-05	0.00146	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	2.64e-05	0.00145	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—LINGO1—multiple sclerosis	2.63e-05	0.00144	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—CXCL10—multiple sclerosis	2.6e-05	0.00143	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—CXCL13—multiple sclerosis	2.49e-05	0.00137	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—CCR1—multiple sclerosis	2.49e-05	0.00137	CbGpPWpGaD
Fexofenadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—multiple sclerosis	2.48e-05	0.00136	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	2.45e-05	0.00135	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—RRM1—multiple sclerosis	2.42e-05	0.00133	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.4e-05	0.00132	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—TAGAP—multiple sclerosis	2.28e-05	0.00125	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—SRM—multiple sclerosis	2.27e-05	0.00125	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	2.26e-05	0.00124	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—CCL5—multiple sclerosis	2.23e-05	0.00123	CbGpPWpGaD
Fexofenadine—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	2.2e-05	0.00121	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.2e-05	0.00121	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.19e-05	0.0012	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—SRM—multiple sclerosis	2.14e-05	0.00117	CbGpPWpGaD
Fexofenadine—ABCB1—Allograft Rejection—TNF—multiple sclerosis	2.11e-05	0.00116	CbGpPWpGaD
Fexofenadine—SLCO1B3—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.08e-05	0.00114	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—BCHE—multiple sclerosis	2.07e-05	0.00114	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	2.07e-05	0.00113	CbGpPWpGaD
Fexofenadine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	2.02e-05	0.00111	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—CCR5—multiple sclerosis	2.01e-05	0.00111	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—S1PR1—multiple sclerosis	1.99e-05	0.00109	CbGpPWpGaD
Fexofenadine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	1.98e-05	0.00109	CbGpPWpGaD
Fexofenadine—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	1.94e-05	0.00107	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—GPC5—multiple sclerosis	1.94e-05	0.00107	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.89e-05	0.00104	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—PTGER4—multiple sclerosis	1.88e-05	0.00103	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.88e-05	0.00103	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—CXCR3—multiple sclerosis	1.81e-05	0.000997	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—CCL3—multiple sclerosis	1.77e-05	0.000974	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—CCR2—multiple sclerosis	1.77e-05	0.00097	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.72e-05	0.000945	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—PTGER4—multiple sclerosis	1.71e-05	0.000937	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—RGS1—multiple sclerosis	1.7e-05	0.000931	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—CXCR3—multiple sclerosis	1.65e-05	0.000905	CbGpPWpGaD
Fexofenadine—SLCO1A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.64e-05	0.000898	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—CNR1—multiple sclerosis	1.63e-05	0.000895	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—BCHE—multiple sclerosis	1.63e-05	0.000893	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.61e-05	0.000886	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—GPR65—multiple sclerosis	1.61e-05	0.000883	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—CCR2—multiple sclerosis	1.6e-05	0.000881	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—CYP24A1—multiple sclerosis	1.6e-05	0.000878	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—CYP27B1—multiple sclerosis	1.6e-05	0.000878	CbGpPWpGaD
Fexofenadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	1.58e-05	0.000867	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—POMC—multiple sclerosis	1.57e-05	0.000864	CbGpPWpGaD
Fexofenadine—HRH1—GPCR ligand binding—CCL2—multiple sclerosis	1.54e-05	0.000845	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	1.51e-05	0.000827	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	1.51e-05	0.000827	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—CNR1—multiple sclerosis	1.48e-05	0.000813	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.47e-05	0.000808	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CCR1—multiple sclerosis	1.47e-05	0.000807	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CXCL13—multiple sclerosis	1.47e-05	0.000807	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—CXCL10—multiple sclerosis	1.47e-05	0.000806	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—GPC5—multiple sclerosis	1.46e-05	0.000803	CbGpPWpGaD
Fexofenadine—SLCO1B1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.4e-05	0.000768	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—BCHE—multiple sclerosis	1.39e-05	0.000763	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.38e-05	0.000757	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—CXCL10—multiple sclerosis	1.33e-05	0.000732	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—CCL5—multiple sclerosis	1.26e-05	0.000694	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—APOE—multiple sclerosis	1.24e-05	0.000684	CbGpPWpGaD
Fexofenadine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	1.21e-05	0.000666	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—RRM1—multiple sclerosis	1.21e-05	0.000665	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—CCL5—multiple sclerosis	1.15e-05	0.00063	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.14e-05	0.000627	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—CCR5—multiple sclerosis	1.14e-05	0.000625	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—IL2RA—multiple sclerosis	1.12e-05	0.000616	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.12e-05	0.000614	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.12e-05	0.000612	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.09e-05	0.000601	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—POMC—multiple sclerosis	1.07e-05	0.000587	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CCL3—multiple sclerosis	1.05e-05	0.000575	CbGpPWpGaD
Fexofenadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.04e-05	0.000572	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—CCR5—multiple sclerosis	1.03e-05	0.000567	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—IL2RA—multiple sclerosis	1.02e-05	0.000559	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—PTGER4—multiple sclerosis	1.01e-05	0.000554	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—PGR—multiple sclerosis	9.93e-06	0.000545	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—APOE—multiple sclerosis	9.78e-06	0.000537	CbGpPWpGaD
Fexofenadine—SLCO1B3—Metabolism—ALB—multiple sclerosis	9.75e-06	0.000535	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CXCR3—multiple sclerosis	9.74e-06	0.000535	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CD28—multiple sclerosis	9.64e-06	0.00053	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CCR2—multiple sclerosis	9.47e-06	0.00052	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—POMC—multiple sclerosis	8.89e-06	0.000488	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CNR1—multiple sclerosis	8.74e-06	0.00048	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—POMC—multiple sclerosis	8.4e-06	0.000461	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—APOE—multiple sclerosis	8.36e-06	0.000459	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—POMC—multiple sclerosis	8.07e-06	0.000443	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—CCL2—multiple sclerosis	7.9e-06	0.000434	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CXCL10—multiple sclerosis	7.87e-06	0.000432	CbGpPWpGaD
Fexofenadine—SLCO1A2—Metabolism—ALB—multiple sclerosis	7.66e-06	0.000421	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—POMC—multiple sclerosis	7.18e-06	0.000395	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—TYK2—multiple sclerosis	7.17e-06	0.000394	CbGpPWpGaD
Fexofenadine—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	7e-06	0.000384	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—BCHE—multiple sclerosis	6.96e-06	0.000382	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CD86—multiple sclerosis	6.88e-06	0.000378	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CCL5—multiple sclerosis	6.77e-06	0.000372	CbGpPWpGaD
Fexofenadine—HRH1—GPCR downstream signaling—IL2—multiple sclerosis	6.57e-06	0.000361	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—BCHE—multiple sclerosis	6.56e-06	0.00036	CbGpPWpGaD
Fexofenadine—SLCO1B1—Metabolism—ALB—multiple sclerosis	6.55e-06	0.00036	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—SPP1—multiple sclerosis	6.27e-06	0.000345	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CCR5—multiple sclerosis	6.1e-06	0.000335	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—IL2RA—multiple sclerosis	6.02e-06	0.00033	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—IL2—multiple sclerosis	5.97e-06	0.000328	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—APOE—multiple sclerosis	5.55e-06	0.000305	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CD80—multiple sclerosis	5.02e-06	0.000276	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—POMC—multiple sclerosis	4.77e-06	0.000262	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—CCL2—multiple sclerosis	4.67e-06	0.000256	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—MAPK1—multiple sclerosis	4.57e-06	0.000251	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—TYK2—multiple sclerosis	4.24e-06	0.000233	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—APOE—multiple sclerosis	4.19e-06	0.00023	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—APOE—multiple sclerosis	3.95e-06	0.000217	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—POMC—multiple sclerosis	3.6e-06	0.000198	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—IL2—multiple sclerosis	3.53e-06	0.000194	CbGpPWpGaD
Fexofenadine—HRH1—Signaling by GPCR—IL6—multiple sclerosis	3.51e-06	0.000193	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—POMC—multiple sclerosis	3.39e-06	0.000186	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—MMP9—multiple sclerosis	3.34e-06	0.000183	CbGpPWpGaD
Fexofenadine—ABCB1—Metabolism—ALB—multiple sclerosis	3.28e-06	0.00018	CbGpPWpGaD
Fexofenadine—CYP2D6—Metabolism—ALB—multiple sclerosis	3.09e-06	0.00017	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—STAT3—multiple sclerosis	2.97e-06	0.000163	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—MYC—multiple sclerosis	2.76e-06	0.000151	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—TGFB1—multiple sclerosis	2.75e-06	0.000151	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—MAPK1—multiple sclerosis	2.7e-06	0.000148	CbGpPWpGaD
Fexofenadine—HRH1—Signaling Pathways—IL6—multiple sclerosis	2.07e-06	0.000114	CbGpPWpGaD
